Anlotinib in combination with TQB2450 in patients with recurrent ovarian cancer (ACTION): A multicenter, single-arm, open-label, phase Ib trial.
暂无分享,去创建一个
Wang Jing | Haihong Jin | Li Zhang | C. Lan | Xin Huang | Fan Yang | Yu Huang | Chang Liu | Jinhua Meng | Rongrong Li | Xue-han Bi | Weihong Zhao | Jingjing Zhao